Results 121 to 130 of about 1,497,536 (354)
The choice of local anesthesia in the treatment of permanent molars in children aged 7–12 years
, 2023 Е. Н. Анисимова +5 more
openalex +2 more sources
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Pre-donation deferral of blood donors in South Indian set-up: An analysis
Asian Journal of Transfusion Science, 2010 Background: It is well known that quite a large number of apparently healthy donors are not able to donate blood successfully because of varied reasons. Aim: We want to analyze the rate and various reasons for deferrals.
Sundar P +4 more
doaj
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Effect of Al2O3addition with concentration (x=0.1%, 0.2%, 0.4%) mol on the crystal structure and physical properties of permanent magnets barium hexaferrite (BaO6Fe2O3) [PDF]
, 2019 Ramlan Ramlan +4 more
openalex +1 more source
Molecular Oncology, EarlyView.We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto +8 more
wiley +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
32. Normalized Survival and Permanent Restoration of NAGLU Activity in the CNS, PNS and Somatic Tissues in MPS IIIB Mice after a Single Intravenous rAAV9-hNAGLU Gene Delivery [PDF]
, 2012 openalex +1 more source